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ing individuals.  Conclusion: These differences in the charac-
teristics of ESBL producers may represent different sources 
of colonization. Most LTC applicants harboured  K. pneumoni-
ae or  E. coli that were probably hospital-acquired whereas 
the  E. coli isolates of many healthy individuals showed simi-
larities to environmental  E. coli .  © 2015 S. Karger AG, Basel 
 Introduction 
 Enterobacteriaceae that produce extended-spectrum 
beta-lactamases (ESBLs) have become a major problem 
worldwide, especially since the occurrence and spread of 
the  bla CTX-M family. Many of these enzymes, in contrast 
to the  bla TEM and  bla SHV groups, are linked to epidemic 
clones  [1] and some of them, e.g. the  bla CTX-M-15 -produc-
ing  Escherichia coli O25b:ST131 and  Klebsiella pneu-
moniae ST11, ST15 and ST147 clonal complexes, have be-
come pandemic both in the nosocomial and community 
settings as well as in long-term care (LTC) facilities  [1–3] . 
The switch from  K. pneumoniae to  E. coli as the major 
ESBL producer species is also linked to the dissemination 
of  bla CTX-M genes  [4] .
 The gastrointestinal tracts of humans and even ani-
mals are obviously a major source of ESBL producer spe-
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 Abstract 
 Aims: We compared the prevalence of extended-spectrum 
beta-lactamase (ESBL) producers in the faecal samples of 
1,109 healthy individuals screened for employment purpos-
es and in 531 asymptomatic individuals applying for long-
term care (LTC).  Methods: Eosin-methylene blue agar plates 
supplemented with 2 mg/l cefotaxime were used to deter-
mine which individuals were ESBL producers. ESBL pheno-
type was confirmed by double-disk synergy test and ESBL 
genes were identified by sequencing. ESBL producers were 
characterized by co-resistance and integron carriage.  Re-
sults: ESBL producers were more frequent in the LTC appli-
cants than in the employment screening individuals (7.2 vs. 
2.0%; p < 0.0001), with 43  Escherichia coli , 18  Klebsiella pneu-
moniae , 1  Klebsiella oxytoca and 1  Proteus mirabilis being 
found. In the employment screening individuals, only  E. coli 
was found. Most ESBL genes (79.4%, 50/63) were  bla CTX-M 
type;  bla CTX-M-15 was more frequent in the LTC applicants (p < 
0.001). Regarding ESBL genes and integron diversity, E. coli 
isolates from the LTC applicants were more similar to 
 K.  pneumoniae than to  E. coli from the employment screen-
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cies  [5, 6] and also serve as a site for the horizontal spread 
of resistance genes  [7] . The duration of asymptomatic 
carriage can be very long, up to several years in some cas-
es  [8] , and international travel contributes to even more 
efficient spreading  [9] . Carriage rates, and therefore the 
risk of colonization, in travelers returning home are high-
est in Southeast Asia  [6, 8] , as high as 69.3%. North  Africa 
and the eastern Mediterranean are also associated with a 
higher carriage risk in travelers  [9] .
 Although a number of studies have been published on 
faecal carriage rates in different populations (both pa-
tients and asymptomatic individuals), colonization pat-
terns have only started to be understood. Therefore, the 
aim of this study was to compare the prevalence of faecal 
carriage and the characteristics of ESBL producers among 
applicants for LTC and individuals screened for employ-
ment purposes.
 Materials and Methods 
 Samples and Isolates 
 A total of 1,640 faecal samples from 2 groups of asymptomatic 
individuals not suffering from infection at the time of sampling 
were investigated between March 2009 and April 2010. Samples 
were collected and sent for screening for enteric pathogens from 
1,109 individuals (300 males and 809 females with a median age of 
34 years, range 15–68 years) being screened for employment eligi-
bility purposes (e.g. jobs at hospitals, kindergartens and food-pro-
cessing plants) and 531 individuals (218 males and 313 females 
with a median age of 75 years, range 0–100 years) who needed to 
be screened prior to admittance to LTC facilities. The vast major-
ity of individuals were located in north-eastern Hungary from the 
EU regions of Northern Hungary and the Northern Great Plain.
 The samples were directly inoculated onto eosin-methylene 
blue agar plates supplemented with 2 mg/l cefotaxime. All colonies 
with different morphology were further identified by means of bio-
chemical tests; enterobacterial isolates were then processed fur-
ther.
 According to Clinical and Laboratory Standards Institute 
guidelines, antibiotic susceptibility testing was performed by the 
disc-diffusion method against imipenem, cefotaxime, ceftazidime, 
cefepime, ciprofloxacin, colistin, trimethoprim–sulfamethoxazole 
(co-trimoxazole), doxycycline, amikacin, gentamicin, tobramycin 
and tigecycline. All isolates showing a decreased susceptibility to 
at least 1 third-generation cephalosporin or to cefepime were test-
ed for ESBL phenotype using the double-disc synergy test (Oxoid, 
Basingstoke, UK) and then re-identified using a MALDI Biotyper 
(Bruker, Bremen, Germany). Imipenem-resistant isolates were 
also tested using the Hodge test as specified in the Clinical and 
Laboratory Standards Institute guidelines.
 In the case of isolates displaying an ESBL phenotype, DNA was 
extracted by heat treatment. PCR amplifications were carried out 
in a MyCycler PCR machine (BioRad, Hercules, Calif., USA). Spe-
cies identification for  K. pneumoniae and  E. coli isolates was con-
firmed by species-specific PCRs  [10, 11] .
 Genetic Relatedness 
 The epidemiological relationship was analyzed by enterobac-
terial repetitive intergenic consensus PCR (ERIC-PCR) with 
ERIC2 and ERIC1R primers (as described earlier  [12] ) and 
pulsed-field gel electrophoresis (PFGE). Plugs were prepared as 
described earlier  [13] , macrorestriction was performed using 
XbaI (Fermentas, Vilnius, Lithuania) in a CHEF DRIII machine 
(Bio-Rad) in 1% SeaKem Gold agarose (Lonza) at 14  °  C. Electro-
phoresis was performed at 6 V/cm, with a reorientation angle of 
120°, and switch times were ramped between 2 and 64 s for 20 h 
for both species. Gels were stained with ethidium bromide and 
visualized under UV light. Banding patterns were analyzed with 
Fingerprinting II software (Bio-Rad). The threshold for probable 
unrelatedness was set at <85% similarity. The Simpson index of 
diversity (D) was calculated to assess diversity, as described ear-
lier  [14] .
 Identification of ESBL Genes 
 The  bla TEM ,  bla SHV ,  bla CTX-M genes were detected by PCR, as 
described previously  [15–17] ;  bla TEM and  bla SHV genes were iden-
tified by sequencing (Macrogen, Amsterdam, The Netherlands) 
using the same primers, while  bla CTX-M genes were identified by 
the sequencing of primers of group-specific PCRs  [18] . Sequence 
alignment and analyses were performed using CLC DNA Work-
bench v4.0 (CLC Bio, Aarhus, Denmark).
 Aminoglycoside Resistance Genes and Characterization of 
Integrons 
 The aminoglycoside resistance genes  aac(3’)-IIa (aacC2) , 
 aac(6’)-Ib (aacA4), aph(3’)-Ia (aphA1) ,  ant(2’)-Ia (aadB) ,  ant(3’)-
Ia (aadA1) ,  armA ,  rmtA and  rmtB were sought for as previously 
described  [19–22] . The detection of class 1 and class 2 integrons 
was performed by PCR assays according to Mazel et al.  [23] and 
the amplification and sequencing of the variable regions were per-
formed as described by White et al.  [24] , using newly designed 
internal primers when necessary. Sequences were assembled in the 
CLC DNA Workbench 4.0 (CLC Bio), and gene cassettes were 
identified using the GenBank (http://www.ncbi.nlm.nih.gov). 
Identification of class 1 and class 2 integrons with variable regions 
of the same size was performed by restriction analysis using at least 
two enzymes for each cassette array, including  Eco RI,  Hind III, 
Mse I and Rsa I (Fermentas). 
 Phylogenetic Analysis of E. coli and Virulence Genes 
 Phylogenetic groups of  E. coli were determined using the mul-
tiplex PCR method developed by Clermont et al.  [25] . Phylogroups 
A and B1 are considered commensal, while groups B2 and D in-
clude strains responsible for extra-intestinal infections  [25] . The 
pandemic O25b-ST131 clone was screened in the isolates of the 
phylogenetic group B2 with a PCR-based assay  [26] .
 A multiplex PCR assay was used to determine the presence of 
virulence factor genes characteristic for enterovirulent  E. coli pa-
thotypes, as described previously  [27] .
 We used PCR with previously described primers to search for 
genes coding for the putative extra-intestinal virulence factors of 
 E. coli , including adhesins ( papC ,  fimH ,  sfaS and  sfa/focDE ), toxins 
( cnf1 and  cvaC ), factors related to iron acquisition ( iutA and  fyuA ), 
the capsule system ( kpsMT II ) and miscellaneous factors ( ibeA , 
PAI,  traT and  csgA )  [28] .
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 Statistical Analysis 
 Prevalences were compared by means of the χ 2 test or the Fish-
er exact test as appropriate. Age distribution in the different 
groups was compared by means of the Kolmogorov-Smirnov test. 
The distribution of genes coding for ESBLs, aminoglycoside-
modifying enzyme genes and co-resistance patterns were all ana-
lyzed by χ 2 test, and the pairwise comparisons derived were ad-
justed with the Bonferroni correction. The association of genes 
with each other or with different characteristics was analyzed us-
ing the Pearson correlation. PAST v3.0 was used to perform the 
statistical tests  [29] . 
 Results 
 Epidemiology of ESBL Producers 
 The overall prevalence of ESBL carriers was 3.7% 
(60/1,640). The LTC facility applicants carried ESBL pro-
ducers (7.2%; 38/531) significantly more frequently (p < 
0.001) than the individuals on employment screening 
(2.0%; 22/1,109). The risk of carriage of ESBL producers 
was not affected by the region where patients lived, by 
their gender or by their age in any of the comparisons.
 Of the 63 ESBL-producing isolates from the 60 pa-
tients, 43  E. coli , 18  K. pneumoniae , 1  Klebsiella oxytoca 
and 1  Proteus mirabilis were identified. Three individuals 
harboured multiple ESBL-producing isolates simultane-
ously ( K. pneumoniae and  E. coli in 2 individuals and 
 K. oxytoca and  E. coli in 1 individual, all from the LTC 
applicant group). Among the individuals on employ-
ment screening, only  E. coli isolates could be found, but 
the proportion of  E. coli and  K. pneumoniae isolates was 
similar (21/41 vs. 18/41) in the LTC facility applicants.
 Out of the 63 ESBL-positive isolates, 50 harboured a 
 bla CTX-M gene; the majority of these were  E. coli (38/50). 
The distribution of ESBL genes in the 2 groups is shown 
in  figure 1 . All isolates carrying  bla CTX-M other than 
 bla CTX-M-15 were  E. coli ; 1  E. coli isolate harboured 
 bla CTX-M-15 and  bla CTX-M-2 simultaneously. All  K. pneu-
moniae and 5  E. coli isolates (11.6%) carried  bla SHV-12 ; 
in  the case of  K.  pneumoniae , 11 isolates harboured 
 bla CTX-M-15 and  bla SHV-12 at the same time. The distribu-
tion of the ESBL genes was significantly different (p = 
0.001) between the 2 study groups;  bla CTX-M-15 was more 
frequent in the LTC applicants (p < 0.001), and the fre-
quencies of other genes were comparable. When com-
paring ESBL gene distribution among  K. pneumoniae 
(all from the LTC applicants),  E. coli from the LTC ap-
plicants and  E. coli from the people on employment 
screening, a significant difference was found (p < 0.001). 
All 3 isolate groups showed significantly different distri-
butions in pairwise comparisons (p < 0.001 to p = 0.026), 
mostly due to the different distribution of  bla CTX-M-15 . In 
addition,  K. pneumoniae carried  bla SHV-12 more fre-
quently than E. coli among the LTC applicants and in the 
employment screening group (p < 0.001).
 Genetic Diversity 
 The genetic diversity among  E. coli isolates was high 
on both ERIC-PCR (data not shown) and PFGE ( fig. 2 ; 
D  = 0.99 and 0.96, respectively). One isolate was not 
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 Fig. 2. Dendrogram generated from macrorestriction patterns of the  E. coli isolates. 
number ESBL gene phylogroup study group
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typeable with ERIC-PCR but its PFGE analysis was 
 successful. The diversity of  E. coli between the 2 groups 
was comparable (D = 0.99 vs. 0.99 and D = 0.94 vs. 0.95, 
respectively). Isolates in the same cluster were not 
 uniform with regard to the ESBL genes and integrons 
carried.
 In contrast, K. pneumoniae isolates were markedly less 
diverse, both with ERIC-PCR (data not shown) and PFGE 
( fig. 3 ; D = 0.58 and 0.31, respectively); a PFGE clone con-
taining 15 of the 18 isolates was detected. Notably, 1 of 
the distinct isolates was the carbapenem nonsusceptible 
isolate.
 Resistance Patterns and Aminoglycoside Resistance 
Genes 
 All ESBL-producing isolates were susceptible to colis-
tin; carbapenem nonsusceptibility (Hodge test: negative) 
was detected in a single  K. pneumoniae isolate harbouring 
 bla SHV-12 . The  K. pneumoniae clone detected was resistant 
to all the drugs tested, except for carbapenem and colistin, 
and it carried the  aac(6’)-Ib gene but no other tested ami-
noglycoside resistance genes.
 As shown in  figure 4 , resistance rates significantly dif-
fered between  E. coli isolates from individuals on employ-
ment screening and on screening for LTC admission in the 
case of ciprofloxacin, amikacin, tobramycin and trime-
thoprim-sulfamethoxazole (p = 0.048 to p < 0.002). When 
comparing commensal vs. pathogenic  E. coli isolates as 
classified by phylogroups, the resistance pattern was simi-
lar; however, the significant differences in ciprofloxacin 
and trimethoprim-sulfamethoxazole disappeared. In con-
trast to the  K. pneumoniae clone, isolates showing resis-
tance to all non-beta-lactam antibiotic groups (except co-
listin) were not found in either  E. coli group.
 In the  E. coli isolates, the presence of the  bla CTX-M-15 
gene correlated positively with ciprofloxacin, amikacin 
and tobramycin resistance ( table 1 ). The gene  bla CTX-M-1 , 
on the contrary, correlated negatively with resistance to 
amikacin and tobramycin.
 The prevalences of aminoglycoside resistance genes 
are shown in  figure 5 ; all isolates were negative for  ant(2’)-
Ia ,  armA , rmtA  and  rmtB  genes. In the case of  E. coli from 
the LTC applicants, aminoglycoside resistance genes 
were distributed unevenly (p = 0.017) with more frequent 
 Fig. 3. Dendrogram generated from macrorestriction patterns of  K. pneumoniae isolates. 
number ESBL gene
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carriage of  aac(6’)-Ib than  aph(3’)-Ia and  ant(3’)-Ia (p = 
0.048 for both comparisons), but not more frequent than 
the carriage of  aac(3’)-IIa . In the  E. coli from the employ-
ment screening group, the gene distribution was also un-
even (p < 0.001), but  ant(3’)-Ia was more dominant than 
 aac(6’)-Ib and  aph(3’)-Ia (p = 0.005 and p = 0.02, respec-
tively). When applying the phylogroup-based classifica-
tion of  E. coli , pathogenic isolates showed a pattern very 
similar to that of the isolates from the LTC applicants, but 
the dominance of  aac(6’)-Ib over  aph(3’)-Ia and  ant(3’)-
Ia was more marked (p = 0.004 for both comparisons). 
The commensal isolates were similar to the isolates from 
the employment screening group.
 The presence of the  bla CTX-M-15 gene in  E. coli was as-
sociated with the presence of  aac(3’)-IIa as well as  aac(6’)-
Ib , and it correlated with the absence of  aph(3’)-Ia and 
 ant(3’)-Ia ( table  1 ). The carriage of  bla CTX-M-1 , in turn, 
was negatively correlated with  aac(6’)-Ib .
 Integrons 
 The  K. pneumoniae clone carried a class 1 integron 
with a single  ant(3’)-1b gene, which was also found in 2 
of the 3 independent isolates. In  E. coli , integron carriage 
correlated negatively with  bla CTX-M-15 ( table 1 ). The car-
riage rate of class 1 integrons was significantly higher in 
the  E. coli from the employment screening group than 
from the LTC applicants (68.2%, 15/22 vs. 28.6%, 6/21; 
p = 0.01). Class 2 integrons were found in 6.3% (4/63) of 
the isolates (3 among the LTC facility applicants and 1 in 
an individual for employment screening); of these, 2 
 E. coli isolates harboured both integron types (1 isolate 
was from the LTC applicant group and the other from the 
employment screening group). 
 Seven and 2 different gene cassette arrays were identi-
fied amongst the class 1 and 2 integrons, respectively 
( fig. 6 ). These arrays did not show any association with 
the ESBL gene carried or the study group of origin.
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 Fig. 4. Resistance rates in ESBL-producing isolates obtained from 
long-term care facility applicants and individuals on employment 
screening. amik = Amikacin; cip = ciprofloxacin; dox = doxycy-
cline; gen  = gentamicin; tig  = tigecycline; tmp + smx  = trime-
thoprim-sulfamethoxazole (co-trimoxazole); tob  = tobramycin. 
 *  p < 0.05;  * *  p < 0.01;  * * *  p < 0.001. 
 Table 1.  Correlation of carriage of blaCTX-M-15 and blaCTX-M-1 with 
resistance to antibiotics and aminoglycoside resistance genes in 
E. coli isolates
blaCTX-M-15 blaCTX-M-1
Ciprofloxacin resistance r = 0.43** n.s.
Gentamicin resistance n.s. n.s.
Amikacin resistance r = 0.58*** r = –0.41**
Tobramycin resistance r = 0.63*** f = –0.39**
Tigecycline resistance n.s. n.s.
Carriage of aac(3’)-IIa r = 0.39* n.s.
Carriage of aac(6’)-Ib r = 0.70*** r = –0.40*
Carriage of aph(3’)-Ia r = –0.35* n.s.
Carriage of ant(3”)-Ia r = –0.36* n.s.
Carriage of class I integron r = –0.49*** n.s.
 n.s.  = Not significant. Bold text represents negative correla-
tions. * p < 0.05; ** p < 0.01; *** p < 0.001.
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Fig. 6. Schematic representation of the various cassette arrange-
ments found in class 1 and class 2 integrons. The arrows display 
different genes. The grey boxes indicate the 3 ′ and 5 ′ conservative 
segments. Integron numbers for class 1 integrons according to the 
Integrall database (http://integrall.bio.ua.pt/?nomenclature) are 
also shown. The number of isolates carrying each cassette array is 
shown on the right.  a  The  P. mirabilis  isolate also carried this array.
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 Phylogrouping of E. coli and Analysis of Virulence 
Genes 
 Phylogenetic group analysis showed that group A cov-
ered 46.5% of strains, followed by groups B2 (25.6%), B1 
(23.3%) and D (4.6%). The commensal  E. coli phylogroup 
A was more frequent in the employment screening group 
(14/22 vs. 6/21; p = 0.02), but phylogroup B2 was more 
frequent in the LTC applicants (9/21 vs. 2/22; p = 0.01). 
All phylogroup B2 isolates belonged to the  bla CTX-M-15 
producer O25b:ST131 pandemic clone. 
 None of the isolates belonged to the entero-virulent 
pathogroups for which tests were conducted. The fre-
quency of the examined extra-intestinal virulence factor 
according to phylogroup is shown in  table 2 . Isolates be-
longing to pathogenic phylogroups showed a higher 
prevalence of the genes  kpsMT II  (p = 0.002) and  fyuA 
 (p < 0.001) than those from commensal phylogroups. The 
genes  sfaS , cnf1 ,  ibeA ,  sfa/focDE  and PAI  were complete-
ly absent from the commensal isolates. The comparison 
 E. coli isolates according to source population yielded 
similar results, but only the prevalence of PAI was sig-
nificantly different (p = 0.017). Virulence factor patterns 
were not linked to the type of ESBL gene  carried.
 Discussion 
 Asymptomatic carriage of ESBL-producing Entero-
bacteriaceae was documented as early as 1989 in hospital 
patients  [30] , and reports of carriage in healthy individu-
als soon followed  [31, 32] . It became obvious that differ-
ent geographical regions show different carriage rates in 
communities, ranging from 0.6 to 11.6% in Europe  [6] , 
with the highest prevalence being reported in LTC appli-
cants from Belgium. Much higher rates have been found 
in other regions, e.g. 63.3% in Egypt  [33] and 69.3% in 
Thailand  [34] . This geographical difference is underlined 
by studies reporting international travel as a risk factor 
for the carriage of ESBL producers  [8, 35, 36] . Faecal car-
riage rates seem to be increasing  [6, 37, 38] .
 The prevalence rate found in this study among healthy 
individuals (those screened for employment purposes) is 
comparable or somewhat lower than rates reported by 
European studies  [39, 40] . In contrast, the LTC applicants 
showed much higher prevalence, closer to that seen in 
hospitalized patients who were free of ESBL-related infec-
tions  [41] a few years earlier and also that found in a con-
temporary study from Belgium targeting a similar patient 
group  [42] .
 The distribution of the ESBL genes in the 2 study pop-
ulations differed. In the  K. pneumoniae and  E. coli from 
the LTC applicants, it was similar to that in a European 
study on ESBL producers from human clinical samples 
 [43] , while higher gene diversity was found in the  E. coli 
from the employment screening group.
 Co-resistance patterns showed similarities with previ-
ous findings, e.g. the association of  bla CTX-M genes with 
ciprofloxacin and amikacin resistance  [44, 45] . Co-resis-
tance, as expected, was highest in  K. pneumoniae  [45] , 
with a single, multi-resistant clone being dominant 
among the isolates. The co-resistance pattern of the 2 
 E. coli types was also very different. Resistance to cipro-
floxacin, amikacin and tobramycin was significantly 
more prevalent in the LTC applicants, with the amikacin 
and tobramycin resistance being caused mainly by car-
riage of the  aac(6’)-Ib gene linked to  bla CTX-M-15  carriage. 
In agreement, it was also shown that ciprofloxacin resis-
tance is associated with aminoglycoside resistance in ES-
BL-producer and non-ESBL producer  E. coli  [46] .
 In contrast, ESBL producers from the employment 
screening individuals were characterized by lower co-re-
sistance rates, a low frequency of  aac(6’)-Ib and a high 
prevalence of  ant(3’)-Ia , a gene which is frequently pres-
ent in the intestinal  E. coli  of healthy individuals  [47] . This 
difference can be attributed to the high frequency of the 
ST131 carrying  bla CTX-M-15 in the LTC applicant group, 
while  bla CTX-M-1 carrier isolates, regardless of origin, were 
characterized by their low rate of co-resistance to other 
antibiotic classes and their lack of the  aac(6’)-Ib gene. In 
addition, several virulence factors were more frequently 
 Table 2.  Distribution of virulence genes according to E. coli phy-
logenetic groups
Gene Number of positive isolates per phylogroup
A
(n = 20)
B1
(n = 10)
B2
(n = 11)
D
(n = 2)
Total
(n = 43)
iutA 6 6 8 1 21 (48.8%)
papC 1 2 3 1 7 (16.3%)
kpsMT II 5 1 8 1 15 (34.9%)
fyuA 3 4 10 1 18 (41.9%)
sfaS 0 0 3 0 3 (7.0%)
cvaC 5 6 4 0 15 (34.9%)
traT 9 10 9 1 29 (67.4%)
cnf1 0 0 2 0 2 (4.6%)
ibeA 0 0 3 0 3 (7.0%)
sfa/focDE 0 0 3 0 3 (7.0%)
PAI 0 0 10 1 11 (25.6%)
fimH 15 10 11 2 38 (88.4%)
csgA 19 10 2 1 32 (74.4%)
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found in the isolates from LTC applicants, also attribut-
able to the higher frequency of ST131 in this group.
 The differences in the distribution of the carried ESBL 
genes and other characteristics between the 2 populations 
in this study may be explained, in our opinion, by the dif-
ferent probable source of colonization. Most carriers in 
the group being screened for work eligibility presumably 
represent acquisition events independent of hospitals 
(rather community-related) whereas the group of LTC 
applicants probably represents mainly nosocomial acqui-
sition. This serves as an explanation for the observations 
that  K. pneumoniae , a typical nosocomial pathogen, was 
absent in the employment screening group, and that the 
 E. coli isolates from the LTC applicants were more similar 
to  K. pneumoniae than to  E. coli isolates from the employ-
ment screening group with regard to a number of charac-
teristics, including (1) a significantly lower diversity of 
the  bla CTX-M genes, (2) a significantly higher frequency of 
 bla CTX-M-15 and (3) the occurrence of aminoglycoside re-
sistance genes  aac(6’)-Ib and  ant(3’)-Ia . This assumption 
is further supported by the lower occurrence of the com-
mensal phylogroup A and the higher occurrence of the 
pathogenic phylogroup B2 in the  E. coli from the LTC 
applicants and the frequent isolation of the pandemic 
ST131 clone from this group as well as by differences in 
the co-resistance patterns. Interestingly, these character-
istics of  E. coli were better explained by origin (i.e. LTC 
applicants vs. employment screening) than by phylogroup-
ing (i.e. commensal vs. pathogenic).
 These data, taken together, suggest that ESBL carriage 
in the community (employment eligibility group) is char-
acterized by different colonization sources. The most ob-
vious source is the exportation of hospital-derived strains 
either by colonized patients who have been discharged or 
by hospital workers; such events may be responsible for 
the introduction of the pathogenic ST131 clone carrying 
 bla CTX-M-15 which causes significant morbidity both in 
hospitals and in the community setting  [48] . The source 
for colonization with isolates carrying  bla SHV may be hor-
izontal gene transfer from exported  K. pneumoniae iso-
lates  [49–51] , while various potential environmental 
sources should also be considered for  bla CTX-M genes oth-
er than bla CTX-M-15 , including food  [52, 53] , companion 
animals  [54, 55], wild animals  [56, 57] surface water  [58] , 
drinking water  [59] and food  [52] , either through direct 
transfer of the resistant bacteria or by the horizontal 
spread of resistance plasmids to human commensal 
 E. coli .
 This assumption is supported by the dominance of 
 bla CTX-M-1 among isolates from the work eligibility 
group and the parallel dominance of  bla CTX-M-1 in ani-
mal-derived Hungarian ESBL-producing  E. coli isolates 
 [53] , in a Polish sample set from water birds  [57] and in 
samples from food and food animals in Switzerland  [52] 
as well as by the high frequency of  bla CTX-M-2 and 
 bla CTX-M-32 in samples originating in food animals  [53, 
60] . These  bla genotypes were found exclusively in the 
individuals screened for work eligibility purposes in this 
study. The relatedness of animal and human isolates has 
also been demonstrated in some studies, pointing to a 
possible zoonotic spread of ESBL-producing  E. coli  [56, 
61] .
 The presented data underline the complex epidemiol-
ogy of ESBL producers in the community setting. The 
ESBL producers or ESBL-encoding genes may reach the 
human gut microbiota in the community setting via two 
main routes. Colonization may be the result of the expor-
tation of nosocomial  K. pneumoniae or  E. coli , character-
ized by a dominance of  bla CTX-M-15 , multiple co-resistance 
to other drug types and frequently by clonal spread. The 
other starting point may be the different environmental 
sources of mainly commensal  E. coli characterized by di-
verse ESBL genes and a high diversity of genotypes of car-
rier bacteria as well as by a low rate of co-resistance. 
Though the extent of contribution to human infection by 
the latter group has still to be established, the increasing 
prevalence demonstrated by several authors  [6 ,  62] is def-
initely cause for alarm.
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